이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade Gliomas

2026년 7월 6일 업데이트: Akshitkumar MIstry

A Randomized Trial of Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade Gliomas

The purpose of this study is to learn whether two alternatives to standard steroid treatment can safely control swelling around a brain tumor after surgery. The study will compare three approaches by placing participants in one of three study groups: standard dexamethasone (a steroid), no routine steroid treatment, and azeliragon, a study drug that may reduce brain swelling through a different pathway. Researchers want to determine whether these alternatives can control swelling while reducing some of the side effects associated with steroid use.

Participants in this study will be randomly assigned to one of three study groups. Participants will undergo their planned brain tumor surgery and receive the treatment assigned to their group. Study procedures are the same as their routine care and include physical and neurological examinations, blood tests, MRI scans, review of medical records, and collection of tumor tissue removed during surgery (optional). Most study visits will occur during routine medical care. Participants will be followed for approximately 24 months after surgery.

연구 개요

상태

아직 모집하지 않음

상세 설명

This study is a randomized Phase II trial because it is designed to evaluate the preliminary efficacy, safety, and feasibility of steroid avoidance and azeliragon as alternatives to dexamethasone for perioperative cerebral edema management in high-grade glioma. The trial uses an intermediate imaging-based efficacy endpoint, enrolls a modest sample size, and is intended to identify promising strategies for subsequent confirmation in a definitive Phase III study.

The trial compares three perioperative strategies-standard dexamethasone, complete steroid avoidance, and RAGE inhibition with azeliragon-to determine their relative safety and effectiveness in controlling cerebral edema following tumor resection. In addition to edema control, the study evaluates clinical, functional, and immunologic outcomes associated with perioperative corticosteroid exposure.

Despite widespread use, dexamethasone lacks prospective evidence defining its optimal perioperative role in glioma patients. This study addresses that gap by rigorously evaluating steroid avoidance and a mechanistically targeted alternative, with the goal of improving patient outcomes while minimizing treatment-related toxicity.

연구 유형

중재적

등록 (추정된)

80

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

  • 이름: UofL Health Brown Cancer Center
  • 전화번호: 502-562-4370

연구 장소

    • Kentucky
      • Louisville, Kentucky, 미국, 40202
        • UofL Health Brown Cancer Center; University of Louisville Hospital
        • 연락하다:
          • UofL Health Brown Cancer Center
          • 전화번호: 502-562-4370
      • Louisville, Kentucky, 미국, 40202
        • UofL Health Jewish Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

Age ≥18 years at the time of screening

  • Newly diagnosed supratentorial tumor with imaging characteristics consistent with high-grade glioma
  • Candidate for craniotomy with planned resection of more than 50% of the contrast-enhancing tumor
  • Midline shift ≤10 mm on preoperative imaging
  • Limited pre-enrollment corticosteroid exposure (≤10 mg dexamethasone total and no chronic steroid use within 30 days)
  • Karnofsky Performance Status ≥60
  • Adequate organ function to undergo surgery and postoperative care as determined by the investigator
  • Ability to provide informed consent and comply with study procedures
  • Agreement to use effective contraception, when applicable

Exclusion Criteria:

  • Participants meeting any of the following will be excluded:

    • Imaging or clinical features highly suggestive of primary CNS lymphoma or metastatic disease
    • Posterior fossa tumors or lesions associated with high risk of brainstem compression
    • Leptomeningeal or widely disseminated disease
    • Clinical conditions requiring immediate corticosteroid therapy
    • Prior exposure to high-dose corticosteroids (>10 mg dexamethasone) or chronic steroid use within 30 days
    • Active systemic illness that increases surgical risk, including uncontrolled infection, coagulopathy, or severe cardiopulmonary disease
    • Pregnancy or breastfeeding
    • Known immunodeficiency or chronic infection requiring immunosuppressive therapy
    • Use of investigational agents within 30 days or concurrent use of immunosuppressive medications not permitted by protocol
    • Known hypersensitivity to azeliragon
    • Inability to undergo MRI due to contraindications such as incompatible implants or severe claustrophobia
    • Life expectancy less than 3 months as determined by the investigator
    • Participation in another interventional clinical trial prior to initiation of standard adjuvant therapy Vulnerable Populations: This study will not enroll children, pregnant or breastfeeding individuals, or prisoners. Individuals with impaired decision-making capacity may be enrolled only when a legally authorized representative is available to provide consent in accordance with institutional and regulatory requirements.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 지지 요법
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Dexamethasone Arm
Standard dexamethasone (steroid) treatment
Potent FDA-approved corticosteroid
간섭 없음: No-dexamethasone Arm
No routine dexamethasone treatment
실험적: Azeliragon Arm
Azeliragon administered for the treatment of brain cancer and to evaluate its capability to control brain swelling around the time of surgery.
orally bioavailable inhibitor of the receptor for advanced glycation endproducts (RAGE)

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
change in peritumoral edema between the preoperative and postoperative period
기간: before the start of adjuvant chemo radiation (up to 6 weeks)
The primary outcome is the change in peritumoral edema between the preoperative and postoperative period. Specifically, it is the ratio of postoperative to preoperative peritumoral edema volume, adjusted for extent of enhancing tumor removed. This outcome is derived from MRI-based volumetric assessment and reflects the effectiveness of each perioperative strategy in controlling cerebral edema while accounting for surgical factors
before the start of adjuvant chemo radiation (up to 6 weeks)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Akshitkumar M Mistry, MD, UofL Health - Brown Cancer Center

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 10월 1일

기본 완료 (추정된)

2029년 8월 1일

연구 완료 (추정된)

2029년 8월 1일

연구 등록 날짜

최초 제출

2026년 6월 30일

QC 기준을 충족하는 최초 제출

2026년 7월 6일

처음 게시됨 (실제)

2026년 7월 9일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 7월 9일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 7월 6일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

IPD 계획 설명

name, address, date of birth, medical history, and other information from your medical records from UofL Health and other institutions involved with this research, as well as from your other healthcare providers (which may include information about HIV status, drug, alcohol or sexually transmitted disease treatment, genetic test results, or mental health treatment)

IPD 공유 기간

Identifiable information will be maintained only as long as necessary for research, regulatory, legal, and record-retention purposes. Until all study activities have been completed.

IPD 공유 액세스 기준

Those who provide funding to the study, outside providers, study safety monitors, government agencies, other sites in the study, data managers, and other agents and contractors used by the study team. Information may also be shared as required by law (for example, to collect or receive information for reporting child abuse or neglect, preventing or controlling disease, injury, or disability, and conducting public health surveillance, investigations or interventions.)

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • ICF

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

Dexamethasone에 대한 임상 시험

3
구독하다